Categories: News

OpenLoop, Leader in Whitelabel Telehealth Delivery, Receives NCQA Certification

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

DES MOINES, Iowa, April 26, 2022 /PRNewswire/ — OpenLoop, an expert in full-stack virtual care delivery services, today announced their Credentials Verification Organization (CVO) Certification from the National Committee for Quality Assurance (NCQA). This comes on the heels of an $8M Series A investment round last month.

NCQA is a private, non-profit organization dedicated to improving healthcare quality. This 12-month long certification underlines OpenLoop’s leadership excellence with an official stamp of approval on its provider staffing, licensing, and credentialing services.

“Our clients choose to partner with OpenLoop because of the unrivaled quality of care our clinicians deliver to their patients. On top of pairing these organizations with leading telehealth providers across all 50 states, we also layer on a depth of live, personalized client support that is unmatched,” said Jon Lensing, Co-founder and CEO of OpenLoop.

OpenLoop has set themselves apart in the industry through the level of care, compassion, and flexibility they offer. As a result, their digital health clients enjoy faster provider staffing, experienced in-network clinicians, continuity of care at every touchpoint, and quality assured virtual visits for their patients.

OpenLoop received NCQA certification for:

  • Application Processing
  • Education & Training
  • DEA Certification
  • License to Practice
  • CVO Application & Attestation
  • Verification of Board Certification
  • Malpractice Claims History
  • Medicare / Medicaid Sanctions
  • Ongoing Monitoring of Sanctions
  • Medical Board Sanctions
  • Work History

“I’m proud to see the strength, diligence, and expertise of OpenLoop’s team gain national third-party recognition by the NCQA. It’s further proof of our unrelenting dedication to top-tier telehealth delivery,” said Christian Williams, Co-founder and COO of OpenLoop. “This certification is a culmination of years of hard work and commitment to expanding access to healthcare across the U.S.”

This certification reinforces OpenLoop’s laser focus on continuing to raise the virtual care delivery bar through their five core, whitelabel service offerings: Provider Staffing, Revenue Cycle Management, Technology Platform, Regulatory & Legal, and Practice Management.

About OpenLoop

OpenLoop was co-founded by CEO, Dr. Jon Lensing, and COO, Christian Williams, with the vision to bring healing anywhere. Their solutions are thoughtfully designed to streamline and simplify go-to-market care delivery for companies offering virtual support to patients across an expansive array of specialties, in all 50 states. OpenLoop’s deep investment in compliant, easy-to-use telehealth technology and top-tier providers continues to set them apart in the industry.

For more information on OpenLoop, visit OpenLoopHealth.com.   

Media Contact Name:
Jess Greiner
334912@email4pr.com 
319-316-3085 

View original content to download multimedia:https://www.prnewswire.com/news-releases/openloop-leader-in-whitelabel-telehealth-delivery-receives-ncqa-certification-301532913.html

SOURCE OpenLoop

Staff

Recent Posts

GE HealthCare drives innovation in theranostics with latest technological advances

GE HealthCare is helping advance clinical and operational excellence in theranostics and molecular imaging through…

11 hours ago

Saudi Arabia Concludes Landmark BIO 2025 Debut as Kingdom Opens Doors to Global Biotech Collaboration

From genomics to regulatory innovation, the Kingdom’s presence in Boston establishes it as a major…

11 hours ago

Enzon and Viskase Enter into Merger Agreement

Enzon and Viskase stockholders will respectively own approximately 15.9% and 84.1% of the combined companyCRANFORD,…

11 hours ago

Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people…

11 hours ago